4,462 Becton, Dickinson and Company $BDX Shares Sold by Guyasuta Investment Advisors Inc.

Guyasuta Investment Advisors Inc. trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 154,195 shares of the medical instruments supplier’s stock after selling 4,462 shares during the quarter. Becton, Dickinson and Company comprises about 1.6% of Guyasuta Investment Advisors Inc.’s holdings, making the stock its 21st biggest holding. Guyasuta Investment Advisors Inc. owned 0.06% of Becton, Dickinson and Company worth $27,601,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Assenagon Asset Management S.A. grew its holdings in shares of Becton, Dickinson and Company by 431.3% during the third quarter. Assenagon Asset Management S.A. now owns 41,185 shares of the medical instruments supplier’s stock valued at $7,372,000 after buying an additional 33,433 shares during the last quarter. Maryland Capital Advisors Inc. increased its position in shares of Becton, Dickinson and Company by 13,900.0% during the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 139 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in Becton, Dickinson and Company by 10.8% in the 3rd quarter. State of Alaska Department of Revenue now owns 29,913 shares of the medical instruments supplier’s stock worth $5,354,000 after acquiring an additional 2,915 shares during the last quarter. Turtle Creek Wealth Advisors LLC raised its holdings in Becton, Dickinson and Company by 248.1% in the 3rd quarter. Turtle Creek Wealth Advisors LLC now owns 10,012 shares of the medical instruments supplier’s stock worth $1,792,000 after acquiring an additional 7,136 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH raised its holdings in Becton, Dickinson and Company by 0.5% in the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,112,958 shares of the medical instruments supplier’s stock worth $199,672,000 after acquiring an additional 5,109 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the transaction, the executive vice president directly owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 6,906 shares of company stock worth $1,265,855. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Stock Up 2.6%

BDX opened at $193.82 on Friday. The stock has a market capitalization of $53.40 billion, a price-to-earnings ratio of 58.38, a PEG ratio of 12.73 and a beta of 0.21. The firm has a 50 day moving average price of $183.74 and a 200-day moving average price of $163.50. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $194.34. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter last year, the company posted $3.68 earnings per share. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Analyst Ratings Changes

Several brokerages have commented on BDX. Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a research note on Friday, August 7th. Bank of America boosted their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, August 31st. UBS Group initiated coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price target on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Finally, Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Seven research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $185.07.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.